Clinical Trial Update: Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial [Phase 2]

View source ↗

Summary

This update reports the Phase 2 REMAIN trial results assessing nivolumab to prevent relapse in patients with acute myeloid leukemia after initial therapy. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-06